Looking Ahead: Strategies To Avoid Resistance
This article was originally published in Pharmaceutical Approvals Monthly
The need to stratify patients by genotyping is also important because of the issue of resistance, according to new research. Targeting BRAF in mutation-positive cancers can result in the upregulation of CRAF in a subset of tumors, causing resistance, Jeffrey Settleman, Ph.D,, scientific director of Massachusetts General Hospital and professor of medicine at Harvard Medical School, and colleagues have found.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class